Feb 8, 2018 2:00 pm EST Abeona Therapeutics Reports Top-Line Data from Phase 1/2 Gene Therapy Trial in MPS IIIA
Feb 7, 2018 8:45 am EST Abeona Therapeutics Reports on Initial Safety and Biopotency Signals in MPS IIIB Gene Therapy Clinical Trial
Feb 2, 2018 8:54 am EST Abeona Therapeutics Announces Upcoming Presentations at the 14th Annual WORLDSymposium
Jan 29, 2018 8:45 am EST Abeona Receives FDA Regenerative Medicine Advanced Therapy Designation for EB-101 Gene Therapy in Epidermolysis Bullosa
Dec 20, 2017 8:45 am EST Abeona Therapeutics Enrolls First Patient in ABO-101 Phase 1/2 Clinical Trial for MPS IIIB
Nov 15, 2017 8:25 am EST Abeona Reports Third Quarter 2017 Financial Results and Recent Business Highlights
Nov 9, 2017 8:45 am EST Abeona Enrolls First Subject in Spain in Ongoing Phase 1/2 Clinical Trial in MPS IIIA
Oct 19, 2017 9:39 am EDT Abeona Announces Closing of $92 Million Underwritten Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
